Cancer Drug Resistance impact factor and ranking
This profile summarizes the journal metrics and publication information available in the current directory record.
Cancer Drug Resistance metric snapshot
Cancer Drug Resistance has a bibliometric profile in this directory for 2025. The publisher recorded for the journal is OAE PUBLISHING INC. Its listed Clarivate Journal Citation Reports (JCR)-based Journal Impact Factor is 5.2. The five-year Journal Impact Factor is 5.3, giving a second citation window for comparison. The journal is recorded in quartile Q1 for its listed JCR category.
Category position and quartile
The recorded JCR category position is 64 out of 326 journals. Based on that rank position, the journal sits within approximately the top 20% of the listed category. Its listed quartile is Q1. Category ranks and quartiles are field-specific and are not measures of the quality of an individual article.
How the citation indicators compare
The five-year Journal Impact Factor (5.3) is 0.1 points higher than the standard Journal Impact Factor (5.2). Without journal self-citations, the Impact Factor is 5.1, a difference of 0.1 points from the listed standard value. The Journal Citation Indicator (JCI) is recorded as 0.76. These measures use different definitions or citation windows, so they are most useful when read together rather than treated as interchangeable scores.
Citation and publication counts
For 2025, the directory record for Cancer Drug Resistance lists total cites: 1,828; total articles: 21; citable items: 54. These fields describe different parts of the JCR record and should not be combined into an article-level quality score.
Citation half-life profile
The cited half-life is 3.8 years, indicating the median age of items that contributed citations to the journal in the reporting framework. The citing half-life is 5.4 years, indicating the median age of references used by the journal’s articles.
Identifiers and verification
Cancer Drug Resistance is identified in this directory by electronic ISSN 2578-532X. The publisher is recorded as OAE PUBLISHING INC. When making submission, library, or research-evaluation decisions, verify the title and identifiers against the journal publisher and the official Clarivate Journal Citation Reports record.
Complete journal information
Use this table to verify the individual metric values, identifiers and publication details stored for this journal.
| Journal name | Cancer Drug Resistance |
|---|---|
| Abbreviated journal | CANCER DRUG RESIST |
| Publisher | OAE PUBLISHING INC |
| Metric year | 2025 |
| Overall rank | 1,901 |
| ISSN | Not available |
| eISSN | 2578-532X |
| Total cites | 1,828 |
| Total articles | 21 |
| Citable items | 54 |
| Cited half-life | 3.8 years |
| Citing half-life | 5.4 years |
| JCR-based Journal Impact Factor | 5.2 |
| 5-Year Impact Factor | 5.3 |
| Impact Factor without journal self-cites | 5.1 |
| Journal Citation Indicator | 0.76 |
| JCR Impact Factor quartile | Q1 |
| JCR category rank | 64/326 |
| Database record updated |
Frequently asked questions
What is the 2025 JCR-based Journal Impact Factor of Cancer Drug Resistance?
The Journal Impact Factor recorded in this directory as a Clarivate Journal Citation Reports (JCR)-based value for Cancer Drug Resistance is 5.2 for the 2025 metric year.
What are the JCR quartile and category rank of Cancer Drug Resistance?
Cancer Drug Resistance is listed with quartile Q1 and category rank 64/326. These values are category-specific and should be verified against the official JCR record when used for formal assessment.
What is the five-year Journal Impact Factor of Cancer Drug Resistance?
The five-year Journal Impact Factor recorded for Cancer Drug Resistance is 5.3. It uses a longer citation window than the standard Journal Impact Factor.
Who publishes Cancer Drug Resistance?
Cancer Drug Resistance is listed in this directory as being published by OAE PUBLISHING INC.
Related journal profiles
Journals in the same approved specialty or subject are shown first, followed by same-publisher or similar-metric records when needed.